Albert Roy Board Member
Albert T. Roy leads the Lupus Research Alliance as President and Chief Executive Officer. He has two decades of executive non-profit experience with extensive research, drug development and executive management experience in the academic and private sectors.
Leading the largest private lupus research funder at the forefront of many of today’s biggest breakthroughs, Mr. Roy is committed to realizing the mission of the Lupus Research Alliance: to find better treatments and ultimately, a cure, for this highly complex disease. With the vision of being able to match the right therapy for each patient, he remains laser focused on producing clinically meaningful results that “allow people with lupus to be the best versions of themselves.”
Al comes to LRA after six years serving as Executive Director of its clinical arm Lupus Therapeutics and will continue in this role until the position is filled. In this role, Mr. Roy expanded Lupus Therapeutics into a clinical research powerhouse, supporting 20 clinical research efforts with 16 partners from major biopharmaceutical companies committed to lupus drug development. A cornerstone of his success has been the formation and expansion of the Lupus Clinical Investigators Network (LuCIN), a network of 57 prestigious academic institutions throughout North America that care for 25,000 people living with lupus.
Addressing health inequities in lupus research and improving clinical research awareness and engagement, particularly among people of color who are underrepresented in clinical research, continues to be a major goal for Al with the introduction of several novel programs aimed at this all-too prevalent issue.
Previously, Al was Vice President of Operations and Research Programs at CureSearch for Children’s Cancer, a multi-million-dollar public charity whose mission is to support targeted and innovative children’s cancer research. CureSearch served as the fiscal, administrative and philanthropic agent for the world’s largest pediatric cancer clinical trials research network, the Children’s Oncology Group (COG). During his tenure there, Al managed a clinical research portfolio exceeding $50 million per year-and coordinated the formation of the COG through strategic partnerships with more than 200 academic research medical centers throughout North America to conduct Phase I, II and III industry-led and investigator-initiated pediatric cancer clinical trials.
Al is a graduate of Ithaca College and received his Master’s Degree from Johns Hopkins University.